| Literature DB >> 25806156 |
Caicun Zhou1, Christian Manegold2.
Abstract
The oxazaphosphorine cytostatic ifosfamide (IFO) has been successfully integrated in the treatment of various hematological and solid tumors. The purpose of this review is to summarize the evidence for its use in lung cancer starting from basic data of preclinical studies followed by a global summary of the phase III and seminal phase II clinical studies. Global in double respect: first covering both the small cell as well as the non-small cell indications, and, second tracing those studies performed in Europe and the United States as well as those from Asian countries.Entities:
Keywords: Lung cancer; chemotherapy; ifosfamide
Year: 2012 PMID: 25806156 PMCID: PMC4367585 DOI: 10.3978/j.issn.2218-6751.2011.12.02
Source DB: PubMed Journal: Transl Lung Cancer Res ISSN: 2218-6751